Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

NCT00005906 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

NIH

Sponsor class

Conditions

Lymphangioleiomyomatosis
Lymphangiomyomas
Pleural Effusions
Ascites

Interventions

DRUG: Octreotide

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)